Sorafenib May Provide Benefit for Locally Advanced, Metastatic Chordomas

Share this content:
Sorafenib may provide clinical benefit for patients with locally advanced or metastatic chordomas.
Sorafenib may provide clinical benefit for patients with locally advanced or metastatic chordomas.

Sorafenib may provide clinical benefit for patients with locally advanced or metastatic chordomas, a new study published online ahead of print in the journal Annals of Oncology has shown.

Because there is consensual treatment for patients with locally advanced or metastatic chordomas, a rare type of sarcoma that occurs in the skull base and along the spine, researchers sought to evaluate the safety and efficacy of sorafenib as a potential treatment.

For the multicenter, open-label, uncontrolled phase 2 trial, researchers enrolled 27 patients with locally advanced or metastatic chordomas between May 2011 and January 2014. Of those, 12 had previously received chemotherapy and molecularly targeted agents to treat their disease.

Results showed an intent-to-treat best objective response rate of 3.7% (95% CI: 0.1, 19.0), a 9-month progression-free rate of 73.0% (95% CI: 46.1, 88.0), and a 12-month overall survival rate of 86.5% (95% CI: 55.8, 96.5).

RELATED: Clinically Relevant Molecular Subtypes in Leiomyosarcoma

Analyses demonstrated similar survival curves among pre-treated patients and non-pre-treated patients.

In regard to safety, 77.8% and 14.8% of patients experienced grade 3 and 4 toxicities, respectively.

The findings suggest that further studies are warranted to assess the value of sorafenib as a treatment for patients with locally advanced or metastatic chordomas.

Reference

  1. Bompas E, Le Cesne A, Tresch-Bruneel E, et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv300.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs